Iron Sucrose
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09146 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 30 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary hyperoxaluria | KG + DL |
| 2 | pancreatitis | KG + DL |
| 3 | tumoral calcinosis, hyperphosphatemic, familial | KG + DL |
| 4 | familial apolipoprotein C-II deficiency | KG + DL |
| 5 | esophageal varices without bleeding | KG + DL |
| 6 | esophageal varices with bleeding | KG + DL |
| 7 | familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome | KG + DL |
| 8 | hyperparathyroidism | KG + DL |
| 9 | hyperlipidemia | KG + DL |
| 10 | immune-mediated necrotizing myopathy | KG + DL |
| 11 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 12 | antisynthetase syndrome | KG + DL |
| 13 | hyperlipidemia due to hepatic triglyceride lipase deficiency | KG + DL |
| 14 | hypertriglyceridemia, familial | KG + DL |
| 15 | hyperlipoproteinemia | KG + DL |
| 16 | inflammatory myopathy with abundant macrophages | KG + DL |
| 17 | idiopathic eosinophilic myositis | KG + DL |
| 18 | focal myositis | KG + DL |
| 19 | lipase deficiency, combined | KG + DL |
| 20 | major hypertriglyceridemia | KG + DL |
| 21 | varicose disease | KG + DL |
| 22 | hepatoportal sclerosis | KG + DL |
| 23 | primitive portal vein thrombosis | KG + DL |
| 24 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 25 | idiopathic copper-associated cirrhosis | KG + DL |
| 26 | hepatopulmonary syndrome | KG + DL |
| 27 | hepatic porphyria | KG + DL |
| 28 | alcoholic cardiomyopathy | KG + DL |
| 29 | hereditary hypercarotenemia and vitamin A deficiency | KG + DL |
| 30 | nephrolithiasis susceptibility caused by SLC26A1 | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.